Other Investigational

Cortistatin

A neuropeptide related to somatostatin that has been studied for anti-inflammatory, neuroendocrine, and cardiovascular effects.

NeuropeptideImmuneInflammationInvestigational

Also referenced as: CST

Also appears in: Hormone · Immune

Public product evidence No certificate records are bound to a tracked Cortistatin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Cortistatin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area
Other research areas

Primary research area: Other. Also surfaces under Hormone · Immune for browsing and discovery.

Body systems
Brain · Immune

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
1

CST

Signal depth
Medium

No FDA label signal · 759 trials · 8260 PubMed results

Preclinical
Research evidence

Current evidence for Cortistatin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Cortistatin has 2 name-matched clinical trials (highest phase: no phased trial) and 8260 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Human (non-phased)
Trial quality
Observational
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
NA The Reliability and Validity Tele-assessment of The TUG Test and 30s-CST NA IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria Arthritis Care & Research · 463 citations Measures of physical performance assessments: Self‐Paced Walk Test (SPWT), Stair Climb Test (SCT), Six‐Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car Task Nature · 427 citations 53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-in Nature · 348 citations The human CST complex is a terminator of telomerase activity Journal Article Efficacy of Intravitreal Faricimab for Diabetic Macular Edema and Analysis of Influencing Factors.
Evidence history
  1. 2026-10-17 Promising → Preclinical Band Promising → Preclinical; +2 PubMed
  2. 2026-10-14 Preclinical → Promising Band Preclinical → Promising; +30 trials; +7 PubMed
  3. 2026-10-01 Promising → Preclinical Band Promising → Preclinical; -8 trials; +2 PubMed
  4. 2026-09-30 Preclinical → Promising Band Preclinical → Promising; +2 PubMed
  5. 2026-09-25 Promising → Preclinical Band Promising → Preclinical; -30 trials; +3 PubMed
  6. 2026-09-23 Preclinical → Promising Band Preclinical → Promising; +15 trials; +1 PubMed
  7. 2026-09-17 Promising → Preclinical Band Promising → Preclinical; -15 trials; +1 PubMed
  8. 2026-09-12 Preclinical → Promising Band Preclinical → Promising; +3 PubMed
  9. 2026-09-11 Promising → Preclinical Band Promising → Preclinical; -15 trials; +1 PubMed
  10. 2026-09-10 Preclinical → Promising Band Preclinical → Promising; +7 trials; +3 PubMed
  11. 2026-09-01 Promising → Preclinical Band Promising → Preclinical; -15 trials
  12. 2026-08-28 Preclinical → Promising Band Preclinical → Promising; -15 trials; +2 PubMed
  13. 2026-08-25 Promising → Preclinical Band Promising → Preclinical; +22 trials
  14. 2026-08-22 Preclinical → Promising Band Preclinical → Promising; -14 trials
  15. 2026-08-18 Promising → Preclinical Band Promising → Preclinical; +8 trials; +1 PubMed
  16. 2026-08-15 Preclinical → Promising Band Preclinical → Promising; +7 trials; +3 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What cortistatin is

Cortistatin is a neuropeptide related to somatostatin with research relevance in inflammation, neuroendocrine signaling, and cardiovascular biology.

Why it matters

It is a good example of a peptide that is scientifically interesting and biologically rich even though it is not a mainstream vendor-market name.

Regulatory context

Cortistatin is not FDA approved as a therapeutic peptide in the United States.

Practical reading note

Adding peptides like cortistatin helps keep the library from becoming only a catalog of the internet’s loudest compounds.